Novelty: New VCaP-CR cell line that shows properties of castration resistant tumors, both in vitro and in vivo.
Value Proposition: Current treatments for metastatic prostate cancer involve castration, resulting in low serum androgen levels. After intervention and treatment, most tumors develop resistance to this therapy and present as castration resistant disease. These cells lines derived from prostate cancer androgen dependent cell lines demonstrate properties of castration resistant tumors. Some of the advantages of these derived cell lines include:
- Androgen independent
- Exhibit properties of castration resistant tumors, both in vitro and in vivo
- Represents valuable model of advanced prostate cancer for further investigation and testing of novel therapeutics
Technical Details: Johns Hopkins researchers have derived the VCaP-CR androgen independent cell line from an androgen dependent cell line model of prostate cancer (
VCaP (ATCC® CRL-2876™)), which was originally developed in the laboratory of Dr. Ken Pienta (
In Vivo. 2001 Mar-Apr;15(2):163-8). Through passaging in castrate animals and serial culturing in medium containing no androgens, they were able to generate these androgen independent sublines. In contrast to the parental cell lines, these newly derived cells grow in the absence of androgens.
Looking for Partners: To develop and commercialize this technology as a research tool to investigate mechanisms involved in castration resistant prostate cancer.
Publications/Associated Cases:
